Capmatinib

Tabrecta

150 MG TabletCanadaMarketedAuthorised 16 Sept 2022

In other countries

The same active substances on other registers, the same brand first.

TabrectaEuropean Union · Novartis Europharm LimitedSame brand
TabrectaCroatiaSame brand
TabrectaItaly · Compressa rivestita con film · Novartis Europharm LimitedSame brand
Tabrecta 150mg, filmomhulde tablettenNetherlands · Filmomhulde tablet · Novartis Europharm LimitedSame brand
Tabrecta 200mg, filmomhulde tablettenNetherlands · Filmomhulde tablet · Novartis Europharm LimitedSame brand
TABRECTA FILM-COATED TABLET 150mgSingapore · 150mg · tablet, film coated · Novartis (Singapore) Pte LTDSame brand
TABRECTA FILM-COATED TABLET 200mgSingapore · 200mg · tablet, film coated · Novartis (Singapore) Pte LTD

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Capmatinib

Tabrecta

150 MG TabletCanadaMarketedAuthorised 16 Sept 2022

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

TabrectaUnited States · 150MG BASE, 200MG BASE · tablet · Novartis Pharm

Documents

The official texts, at the regulator.

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Capmatinib
Strength: 150 MG
Dosage form: Tablet
Route: Oral
Register: Canada (Health Canada)
Status: Marketed
Authorised: 16 Sept 2022
Registration: DIN 02527391
Marketing authorisation holder: Novartis Pharmaceuticals Canada INC
ATC code: L01EP01
Group: Antineoplastic and immunomodulating agents
Supply: PRESCRIPTION